Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy

Epileptic Disorders

Volumn 11, Issue 1, 2009, Pages 61-66

  Marinas, Ainhoa ^a   Villanueva, Vicente ^b   Giráldez, Beatriz G ^a   Molins, Albert ^c   Salas Puig, Javier ^d   Serratosa, Jose M ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Absence; Generalized seizures; Idiopathic generalized epilepsy; Myoclonic; Tonic clonic seizures; Zonisamide

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADD ON THERAPY; ADOLESCENT; ADULT; ANOREXIA; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERALIZED EPILEPSY; HEADACHE; HUMAN; IDIOPATHIC DISEASE; IRRITABILITY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; EPILEPSY, GENERALIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65349151863     PISSN: 12949361     EISSN: 19506945     Source Type: Journal    
DOI: 10.1684/epd.2009.0239     Document Type: Article

References (26)

1. Arzimanoglou A, Rahbani AZ. Zonisamide for the treatment of epilepsy. Expert Rev Neurother 2006; 6: 1283-92.
2. Benbadis SR. Practical Management Issues for Idiopathic Generalized Epilepsies. Epilepsia 2005; 46: 125-32.
3. Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005; 46: 31-41.
4. Commission on classification and terminology of the International League Against Epilepsy, 1989. Proposal for revised classification of epilepsy and epileptic syndromes. Epilepsia 1989; 30: 389-99.
5. Faught E, Ayala R, Montouris GG, et al. Zonisamide 922 Trial Group, 2001. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774-9.
6. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252-60.
7. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261-73.
8. Futatsugi Y, Riviello Jr. JJ. Mechanisms of generalized absence epilepsy. Brain Dev 1998; 20: 75-9.
9. Glauser TA, Pellock JM. Zonisamide in paediatric epilepsy: review of the Japanese experience. J Child Neurol 2002; 17: 87-96.
10. Iinuma K, Haginoya K. Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi- institutional survey. Seizure 2004; 13: 34-9.
11. Jallon P, Latour P. Epidemiology of Idiopathic Generalized Epilepsies. Epilepsia 2005; 46: 10-4.
12. Kim D, Song I, Keum S, et al. Lack of the burst firing of thalamo- cortical relay neurons and resistance to absence seizures in mice lacking alpha (1G) T-type Ca(2+) channels. Neuron 2001; 31: 35-45.
13. Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockage by zonisamide. Seizure 1996; 5:115-9.
14. Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004; 6: 267-70.
15. Kothare SV, Kaleyias J, Mostofi N, et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr Neurol 2006;34:351-4.
16. Ohtahara S, Yamatogi Y. Safety of zonisamide therapy: prospective follow-up survey. Seizure 2004; 13: 50-5.
17. Ohtahara S. Zonisamidein themanagementofepilepsy-Japanese experience. Epilepsy Research 2006; 68S: S25-33.
18. O'Rourke D, Flynn C, White M, et al. Potential efficacy of zonisa-mide in refractory juvenile myoclonic epilepsy: retrospective evi-dencefrom an Irish compassionate-use case series. Ir Med J 2007; 100: 431-3.
19. Sackellares JC, Ramsay RE, Wilder BJ, et al. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004; 45: 610-7.
20. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67-73.
21. Seki T, Noboru K, Maezawa M. Effects of zonisamide monother- apy in children with epilepsy. Seizure 2004; 13S: S26-32.
22. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T- type calcium channels in cultured neurons of rat cerebral cortex. Epilepsy Res 1992; 12: 21-7.
23. Szaflarski JP. Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy. Epilepsy Behav 2004;5:1024-6.
24. Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Research2005; 64: 31-4.
25. Yagi K,SeinoM. Methodological requirementsforclinical trialsin refractory epilepsies-our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 79-85.
26. Yamauchi T, Aikawa H. Efficacy of zonisamide: our experience. Seizure 2004; 13: 41-8.